Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
作者: Luis HernandezHiroyo KuwabaraAnshul ShahKaoru YamabeHeather BurnettKyle FahrbachMaria KoufopoulouRyuichi Iwakiri
作者单位: 1Evidera Inc, 500 Totten Pond Road, 5th Floor, 02451, Waltham, MA, USA
2Takeda Pharmaceutical Company Ltd, 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, 103-8668, Tokyo, Japan
3Evidera Inc, 7575 Trans-Canada Hwy, Suite 404, H4T 1V6, St-Laurent, QC, Canada
4Evidera Inc, The Ark, 201 Talgarth Road, Hammersmith, W6 8BJ, London, United Kingdom
刊名: PharmacoEconomics, 2020, Vol.38 (4), pp.69-84
来源数据库: Springer Nature Journal
DOI: 10.1007/s40273-019-00841-1
英文摘要: Abstract(#br)Background(#br)Vedolizumab (VDZ) was approved by the Japanese Ministry of Health, Labor and Welfare in 2018 for the treatment of patients with moderate-to-severe active ulcerative colitis (UC). The comparative cost-effectiveness of VDZ compared with other biologics is unknown in Japan. This information could be useful for decision makers at the time of repricing biologics for the treatment of patients with moderate-to-severe UC. Objective(#br)The aim was to assess the cost-effectiveness of VDZ versus other branded biologics for the treatment of patients with moderate-to-severe UC who were anti-tumor necrosis factor (TNF)-naïve, from the Japanese public healthcare payer perspective. Methods(#br)A hybrid decision tree/Markov model was developed to predict the number of patients...
全文获取路径: Springer Nature  (合作)
分享到:
来源刊物:
影响因子:2.861 (2012)

×